Compare UNTY & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNTY | STTK |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.8M | 652.4M |
| IPO Year | 2014 | 2020 |
| Metric | UNTY | STTK |
|---|---|---|
| Price | $54.69 | $5.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $68.55 | $15.22 |
| AVG Volume (30 Days) | 38.8K | ★ 1.2M |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | 39.66 | ★ 53.02 |
| EPS | ★ 2.82 | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $6.21 | N/A |
| Revenue Next Year | $9.62 | N/A |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.34 | $1.70 |
| 52 Week High | $62.50 | $8.33 |
| Indicator | UNTY | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 37.16 | 42.09 |
| Support Level | $54.13 | $5.85 |
| Resistance Level | $57.12 | $7.83 |
| Average True Range (ATR) | 1.19 | 0.47 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 22.48 | 28.95 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. The Company has elected to become a financial holding company pursuant to regulations of the Board of Governors of the Federal Reserve System (the FRB). The Company's primary business is ownership and supervision of the Bank. The Company and the Bank derive a majority of their revenue from net interest income (i.e., the difference between the interest received on loans and securities and the interest paid on deposits and borrowings). The Company, through the Bank, conducts a traditional and community-oriented commercial banking business and services, personal and business checking accounts, time deposits, money market accounts, savings accounts, credit cards, automated teller service, and others.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.